Safety and efficacy of endovascular treatment in pediatric severe cerebral venous sinus thrombosis
10.3760/cma.j.cn101070-20231228-00459
- VernacularTitle:血管内治疗儿童重型脑静脉窦血栓的安全性及疗效分析
- Author:
Xiaojie FU
1
;
Tao QUAN
;
Yongjie YUAN
;
Haowen XU
;
Sheng GUAN
Author Information
1. 郑州大学第一附属医院神经介入科，郑州 450052
- Keywords:
Child;
Cerebral venous sinus thrombosis;
Endovascular treatment;
Mechanical thrombectomy;
Intrasinus thrombolysis
- From:
Chinese Journal of Applied Clinical Pediatrics
2024;39(7):505-509
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To study the safety and efficiency of endovascular treatment in pediatric severe cerebral venous sinus thrombosis(CVST).Methods:This was a case series study.Data of pediatric severe CVST patients who received endovascular treatment in the Department of Neurointerventional, the First Affiliated Hospital of Zhengzhou University from January 2016 to December 2023 were retrospectively analyzed.The technical success rate, periprocedural complications, neurologic and radiologic outcomes were collected to study the safety and efficacy of endovascular treatment in pediatric severe CVST.Results:A total of 15 patients were included in this study, including 6 males(40.0%) and 9 females(60.0%) with a mean age of(14.60±2.26) years.The modified Rankin Scale score(mRS) before endovascular treatment was(3.47±1.06) points, and the time from onset to endovascular treatment was 17(12-26) days.Thirteen patients(86.7%) received mechanical thrombectomy through catheter aspiration and/or stent-retriever thrombectomy followed or not followed by intrasinus thrombolysis(IST), and 2 patients(13.3%) received IST only.The technical success rate was 100%.Three patients(20.0%) had periprocedural complications.Ten patients(66.7%) had mRS≤2 points at discharge.Twelve patients(80.0%) had valuable neurologic and radiologic follow-ups with a duration of 9.5(3.5-19.0) months, and they all had mRS≤2 points.Among the 12 patients, 8(66.7%) had good cerebral venous recanalization.Conclusions:Endovascular treatment is technically feasible in pediatric severe CVST patients, with acceptable safety and efficacy.
